Pouw, Richard B. http://orcid.org/0000-0003-3469-8454
Ricklin, Daniel http://orcid.org/0000-0001-6140-0233
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (31003A_176104, CRSK-3_196744)
Universität Basel (3PH1062)
Universität Basel
Article History
Received: 27 August 2021
Accepted: 14 September 2021
First Online: 26 October 2021
Change Date: 6 March 2022
Change Type: Update
Change Details: The following funding note has been inserted: Open access funding provided by University of Basel.
Declarations
:
: DR and RBP are co-inventors of patents or patent applications describing therapeutic complement modulators, some of which have been licensed to Amyndas Pharmaceuticals and Gemini Therapeutics. DR has received compensation for invited lectures and/or advisory services from Roche, Novartis, Alexion, Sobi, and Greenovation.